Evelo Biosciences, Inc.
EVLO
$0.0003
-$0.0002-40.00%
OTC PK
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.48% | -33.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.49% | -29.89% | |||
| Operating Income | 40.49% | 29.89% | |||
| Income Before Tax | 40.68% | 17.17% | |||
| Income Tax Expenses | -107.30% | 60.69% | |||
| Earnings from Continuing Operations | 41.41% | 16.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.41% | 16.72% | |||
| EBIT | 40.49% | 29.89% | |||
| EBITDA | 40.00% | 30.35% | |||
| EPS Basic | 81.20% | 17.22% | |||
| Normalized Basic EPS | 80.17% | 26.02% | |||
| EPS Diluted | 81.20% | 17.22% | |||
| Normalized Diluted EPS | 80.17% | 26.02% | |||
| Average Basic Shares Outstanding | 211.61% | 0.60% | |||
| Average Diluted Shares Outstanding | 211.61% | 0.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||